Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma

[1]  A. Deisseroth,et al.  Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy , 2006, Cancer Gene Therapy.

[2]  J. Mathis,et al.  Oncolytic adenoviruses – selective retargeting to tumor cells , 2005, Oncogene.

[3]  J. Mathis,et al.  Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system , 2005, Breast Cancer Research.

[4]  J. Mathis,et al.  Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system , 2005, Cancer biology & therapy.

[5]  H. Namba,et al.  Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells , 2005, Cancer Gene Therapy.

[6]  D. Nettelbeck,et al.  Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells , 2004, Gene Therapy.

[7]  M. Andreeff,et al.  Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. , 2004, Journal of the National Cancer Institute.

[8]  M. Aprahamian,et al.  Carrier cell‐mediated delivery of oncolytic parvoviruses for targeting metastases , 2004, International journal of cancer.

[9]  D. Nettelbeck,et al.  Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. , 2004, Molecular cancer therapeutics.

[10]  D. Nettelbeck,et al.  Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter , 2004, Gene Therapy.

[11]  B. Liu,et al.  Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  D. Curiel,et al.  Approaches to Utilize Mesenchymal Progenitor Cells as Cellular Vehicles , 2003, Stem cells.

[13]  D. Curiel,et al.  Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. , 2003, Cancer research.

[14]  R. Alemany,et al.  The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  D. Nettelbeck,et al.  Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. , 2002, Cancer research.

[16]  M. Andreeff,et al.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. , 2002, Cancer research.

[17]  L. Cornelius,et al.  The role of chemokines in melanoma tumor growth and metastasis. , 2002, The Journal of investigative dermatology.

[18]  Y. Iwadate,et al.  Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir , 2000, Cancer Gene Therapy.

[19]  A. Jacobs,et al.  Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  P. Watkins,et al.  Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. , 1999, Experimental hematology.

[21]  P. Hebda,et al.  Transplanted fetal fibroblasts: Survival and distribution over time in normal adult dermis compared with autogenic, allogenic, and xenogenic adult fibroblasts , 1999, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[22]  N. Michael,et al.  Genomic Organization and Functional Characterization of the Chemokine Receptor CXCR4, a Major Entry Co-receptor for Human Immunodeficiency Virus Type 1* , 1998, The Journal of Biological Chemistry.

[23]  D. Curiel,et al.  Cellular vehicles for cancer gene therapy: current status and future potential. , 2004, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[24]  K. Pienta,et al.  Prostate Cancer Metastasis to Bone Use of the Stromal Cell-derived Factor-1 / CXCR 4 Pathway in Updated Version , 2002 .

[25]  R. Alemany,et al.  A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.